Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Adipocytes promote ovarian cancer chemoresistance.

Yang J, Zaman MM, Vlasakov I, Roy R, Huang L, Martin CR, Freedman SD, Serhan CN, Moses MA.

Sci Rep. 2019 Sep 16;9(1):13316. doi: 10.1038/s41598-019-49649-1.

2.

Tumor-Derived Extracellular Vesicles Breach the Intact Blood-Brain Barrier via Transcytosis.

Morad G, Carman CV, Hagedorn EJ, Perlin JR, Zon LI, Mustafaoglu N, Park TE, Ingber DE, Daisy CC, Moses MA.

ACS Nano. 2019 Sep 10. doi: 10.1021/acsnano.9b04397. [Epub ahead of print]

PMID:
31479239
3.

Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.

Guo P, Yang J, Huang J, Auguste DT, Moses MA.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18295-18303. doi: 10.1073/pnas.1904697116. Epub 2019 Aug 26.

PMID:
31451668
4.

Molecular Mechanisms of p63-Mediated Squamous Cancer Pathogenesis.

Moses MA, George AL, Sakakibara N, Mahmood K, Ponnamperuma RM, King KE, Weinberg WC.

Int J Mol Sci. 2019 Jul 23;20(14). pii: E3590. doi: 10.3390/ijms20143590. Review.

5.

Quantitative Analysis of Different Cell Entry Routes of Actively Targeted Nanomedicines Using Imaging Flow Cytometry.

Guo P, Huang J, Moses-Gardner A, Smith ER, Moses MA.

Cytometry A. 2019 Aug;95(8):843-853. doi: 10.1002/cyto.a.23848. Epub 2019 Jul 11.

PMID:
31294926
6.

Intersection of the p63 and NF-κB pathways in epithelial homeostasis and disease.

King KE, George AL, Sakakibara N, Mahmood K, Moses MA, Weinberg WC.

Mol Carcinog. 2019 Sep;58(9):1571-1580. doi: 10.1002/mc.23081. Epub 2019 Jul 8. Review.

PMID:
31286584
7.

Brainwashed by extracellular vesicles: the role of extracellular vesicles in primary and metastatic brain tumour microenvironment.

Morad G, Moses MA.

J Extracell Vesicles. 2019 Jun 27;8(1):1627164. doi: 10.1080/20013078.2019.1627164. eCollection 2019. Review.

8.

Metalloproteinases and their roles in human cancer.

Roy R, Morad G, Jedinak A, Moses MA.

Anat Rec (Hoboken). 2019 Jun 5. doi: 10.1002/ar.24188. [Epub ahead of print]

PMID:
31168956
9.

ITGA2 as a potential nanotherapeutic target for glioblastoma.

Guo P, Moses-Gardner A, Huang J, Smith ER, Moses MA.

Sci Rep. 2019 Apr 17;9(1):6195. doi: 10.1038/s41598-019-42643-7.

10.

Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis.

Guo P, Yang J, Liu D, Huang L, Fell G, Huang J, Moses MA, Auguste DT.

Sci Adv. 2019 Mar 20;5(3):eaav5010. doi: 10.1126/sciadv.aav5010. eCollection 2019 Mar.

11.

Physical and Family History Variables Associated With Neurological and Cognitive Development in Sturge-Weber Syndrome.

Day AM, McCulloch CE, Hammill AM, Juhász C, Lo WD, Pinto AL, Miles DK, Fisher BJ, Ball KL, Wilfong AA, Levin AV, Thau AJ, Comi AM; National Institute of Health Sponsor: Rare Disease Clinical Research Consortium (RDCRN) Brain and Vascular Malformation Consortium (BVMC) SWS Investigator Group, Koenig JI, Lawton MT, Marchuk DA, Moses MA, Freedman SF, Pevsner J.

Pediatr Neurol. 2019 Jul;96:30-36. doi: 10.1016/j.pediatrneurol.2018.12.002. Epub 2018 Dec 20.

PMID:
30853154
12.

Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study.

Woodworth DC, Dagher A, Curatolo A, Sachdev M, Ashe-McNalley C, Naliboff BD, Labus JS, Landis JR, Kutch JJ, Mayer EA, Lee RS, Moses MA, Ellingson BM; MAPP Research Network.

PLoS One. 2018 Dec 5;13(12):e0206807. doi: 10.1371/journal.pone.0206807. eCollection 2018.

13.

Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.

Jedinak A, Loughlin KR, Moses MA.

Oncotarget. 2018 Aug 21;9(65):32534-32550. doi: 10.18632/oncotarget.25946. eCollection 2018 Aug 21. Review.

14.

Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70).

Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C, Young ZT, Chernova M, Journey SN, Weissman JS, Hann B, Jacobson MP, Neckers L, Gestwicki JE.

J Med Chem. 2018 Jul 26;61(14):6163-6177. doi: 10.1021/acs.jmedchem.8b00583. Epub 2018 Jul 13.

15.

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.

Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, Wells C, Lee S, Zuehlke AD, Shao H, Bingman WE 3rd, Kumar V, Malhotra SV, Weigel NL, Gestwicki JE, Trepel JB, Neckers LM.

Cancer Res. 2018 Jul 15;78(14):4022-4035. doi: 10.1158/0008-5472.CAN-17-3728. Epub 2018 May 15.

16.

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells.

Huang J, Guo P, Moses MA.

J Vis Exp. 2018 Feb 16;(132). doi: 10.3791/57035.

PMID:
29553530
17.

Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines.

Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA, Auguste DT.

Nano Lett. 2018 Apr 11;18(4):2254-2262. doi: 10.1021/acs.nanolett.7b04801. Epub 2018 Mar 12.

PMID:
29505261
18.

Nanomaterial Preparation by Extrusion through Nanoporous Membranes.

Guo P, Huang J, Zhao Y, Martin CR, Zare RN, Moses MA.

Small. 2018 May;14(18):e1703493. doi: 10.1002/smll.201703493. Epub 2018 Feb 22. Review.

PMID:
29468837
19.

Phosphorylation induced cochaperone unfolding promotes kinase recruitment and client class-specific Hsp90 phosphorylation.

Bachman AB, Keramisanou D, Xu W, Beebe K, Moses MA, Vasantha Kumar MV, Gray G, Noor RE, van der Vaart A, Neckers L, Gelis I.

Nat Commun. 2018 Jan 17;9(1):265. doi: 10.1038/s41467-017-02711-w.

20.

Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.

Gordon LB, Campbell SE, Massaro JM, D'Agostino RB Sr, Kleinman ME, Kieran MW, Moses MA.

Pediatr Res. 2018 May;83(5):982-992. doi: 10.1038/pr.2018.9. Epub 2018 Feb 28.

PMID:
29342131
21.

Nanoparticle elasticity directs tumor uptake.

Guo P, Liu D, Subramanyam K, Wang B, Yang J, Huang J, Auguste DT, Moses MA.

Nat Commun. 2018 Jan 9;9(1):130. doi: 10.1038/s41467-017-02588-9.

22.

Heat shock protein 90: its inhibition and function.

Zuehlke AD, Moses MA, Neckers L.

Philos Trans R Soc Lond B Biol Sci. 2018 Jan 19;373(1738). pii: 20160527. doi: 10.1098/rstb.2016.0527. Review.

23.

Alpha band frequency differences between low-trait and high-trait anxious individuals.

Ward RT, Smith SL, Kraus BT, Allen AV, Moses MA, Simon-Dack SL.

Neuroreport. 2018 Jan 17;29(2):79-83. doi: 10.1097/WNR.0000000000000915.

PMID:
29189634
24.

Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks.

Lin RZ, Lee CN, Moreno-Luna R, Neumeyer J, Piekarski B, Zhou P, Moses MA, Sachdev M, Pu WT, Emani S, Melero-Martin JM.

Nat Biomed Eng. 2017;1. pii: 0081. doi: 10.1038/s41551-017-0081. Epub 2017 Jun 13.

25.

ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.

Roy R, Dagher A, Butterfield C, Moses MA.

Mol Cancer Res. 2017 Nov;15(11):1608-1622. doi: 10.1158/1541-7786.MCR-17-0188. Epub 2017 Aug 1.

26.

Urinary kallikrein 10 predicts the incurability of gastric cancer.

Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y, Iwasaki H, Nomura S, Hayashi N, Mori Y, Kataoka H, Moses MA, Joh T.

Oncotarget. 2017 Apr 25;8(17):29247-29257. doi: 10.18632/oncotarget.16453.

27.

A quantitative method for screening and identifying molecular targets for nanomedicine.

Guo P, Yang J, Bielenberg DR, Dillon D, Zurakowski D, Moses MA, Auguste DT.

J Control Release. 2017 Oct 10;263:57-67. doi: 10.1016/j.jconrel.2017.03.030. Epub 2017 Mar 22.

28.

Characterization of dormant and active human cancer cells by quantitative phase imaging.

Guo P, Huang J, Moses MA.

Cytometry A. 2017 May;91(5):424-432. doi: 10.1002/cyto.a.23083. Epub 2017 Mar 17.

29.

Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.

Dagher A, Curatolo A, Sachdev M, Stephens AJ, Mullins C, Landis JR, van Bokhoven A, El-Hayek A, Froehlich JW, Briscoe AC, Roy R, Yang J, Pontari MA, Zurakowski D, Lee RS, Moses MA; MAPP Research Network.

BJU Int. 2017 Jul;120(1):130-142. doi: 10.1111/bju.13832. Epub 2017 Apr 11.

30.

ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.

Guo P, Yang J, Jia D, Moses MA, Auguste DT.

Theranostics. 2016 Jan 1;6(1):1-13. doi: 10.7150/thno.12167. eCollection 2016.

31.

Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases.

Yang J, Roy R, Jedinak A, Moses MA.

Cancer J. 2015 Jul-Aug;21(4):327-36. doi: 10.1097/PPO.0000000000000139. Review.

PMID:
26222086
32.

Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins.

Nakayama H, Huang L, Kelly RP, Oudenaarden CR, Dagher A, Hofmann NA, Moses MA, Bischoff J, Klagsbrun M.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):126-32. doi: 10.1016/j.bbrc.2015.06.087. Epub 2015 Jun 15.

33.

The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.

Hofmann NA, Yang J, Trauger SA, Nakayama H, Huang L, Strunk D, Moses MA, Klagsbrun M, Bischoff J, Graier WF.

Br J Pharmacol. 2015 Aug;172(16):4107-18. doi: 10.1111/bph.13196. Epub 2015 Jun 26.

34.

Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.

Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA.

BMC Cancer. 2015 Apr 11;15:259. doi: 10.1186/s12885-015-1284-z.

35.

The GLU that holds cancer together: targeting GLUtamine transporters in breast cancer.

Moses MA, Neckers L.

Cancer Cell. 2015 Mar 9;27(3):317-9. doi: 10.1016/j.ccell.2015.02.010.

36.

The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.

Moses MA, Henry EC, Ricke WA, Gasiewicz TA.

Cancer Prev Res (Phila). 2015 Mar;8(3):249-57. doi: 10.1158/1940-6207.CAPR-14-0224. Epub 2015 Jan 20.

37.

Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.

Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, Joh T, Moses MA.

Cancer Prev Res (Phila). 2015 Mar;8(3):240-8. doi: 10.1158/1940-6207.CAPR-14-0229. Epub 2015 Jan 15.

38.

The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells.

Jia D, Huang L, Bischoff J, Moses MA.

FASEB J. 2015 Apr;29(4):1371-82. doi: 10.1096/fj.14-258947. Epub 2014 Dec 30.

39.

The management of midline frontonasal dermoids: a review of 55 cases at a tertiary referral center and a protocol for treatment.

Moses MA, Green BC, Cugno S, Hayward RD, Jeelani NU, Britto JA, Bulstrode NW, Dunaway DJ.

Plast Reconstr Surg. 2015 Jan;135(1):187-96. doi: 10.1097/PRS.0000000000000833.

PMID:
25285685
40.

ICAM-1 as a molecular target for triple negative breast cancer.

Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14710-5. doi: 10.1073/pnas.1408556111. Epub 2014 Sep 29.

41.

Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA.

J Urol. 2015 Feb;193(2):722-9. doi: 10.1016/j.juro.2014.08.093. Epub 2014 Aug 25.

42.

Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.

Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA.

Br J Cancer. 2014 Oct 28;111(9):1772-9. doi: 10.1038/bjc.2014.462. Epub 2014 Aug 19.

43.

Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo.

Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA.

Am J Pathol. 2014 Jul;184(7):2099-110. doi: 10.1016/j.ajpath.2014.03.006.

44.

Matrilin-1 is an inhibitor of neovascularization.

Foradori MJ, Chen Q, Fernandez CA, Harper J, Li X, Tsang PC, Langer R, Moses MA.

J Biol Chem. 2014 May 16;289(20):14301-9. doi: 10.1074/jbc.M113.529982. Epub 2014 Apr 1.

45.

Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade.

Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT.

Mol Pharm. 2014 Mar 3;11(3):755-65. doi: 10.1021/mp4004699. Epub 2014 Feb 12.

46.

Urine vascular biomarkers in Sturge-Weber syndrome.

Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM.

Vasc Med. 2013 Jun;18(3):122-8. doi: 10.1177/1358863X13486312.

PMID:
23720035
47.

Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.

Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA.

Blood. 2013 Jan 24;121(4):707-15. doi: 10.1182/blood-2012-05-433045. Epub 2012 Dec 3.

48.

Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.

Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR.

Am J Pathol. 2012 Nov;181(5):1573-84. doi: 10.1016/j.ajpath.2012.07.030. Epub 2012 Sep 27.

49.

Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.

Yang J, McNeish B, Butterfield C, Moses MA.

FASEB J. 2013 Jan;27(1):45-50. doi: 10.1096/fj.12-211730. Epub 2012 Sep 14.

50.

Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.

Guo P, You JO, Yang J, Moses MA, Auguste DT.

Biomaterials. 2012 Nov;33(32):8104-10. doi: 10.1016/j.biomaterials.2012.07.043. Epub 2012 Aug 9.

Supplemental Content

Loading ...
Support Center